The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Novartis Pharmaceuticals Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
- 2025 (10)
- 2024 (20)
- 2023 (44)
- 2022 (38)
- 2021 (36)
- 2020 (58)
- 2019 (31)
- 2018 (47)
- 2017 (11)
- 2016 (44)
- 2015 (37)
- 2014 (10)
- 2013 (12)
- 2012 (6)
- 2011 (6)
- 2010 (28)
- 2009 (4)
- 2008 (15)
- 2007 (1)
- 2006 (4)
- 2005 (11)
- 2004 (4)
- 2003 (5)
- 2002 (7)
- 2001 (5)
- 2000 (8)
- 1999 (2)
- 1998 (2)
- 1997 (4)
- 1996 (4)
- 1995 (4)
- 1993 (10)
- 1992 (3)
- 1991 (16)
Sponsor content
547 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Novartis Pharmaceuticals Australia Pty Ltd - Surgical procedure kit, ophthalmic, medicated, single-use.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SIMULECT basiliximab (rmc) 20mg powder for injection vial.
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Dec-2024Prescription medicine evaluationActive ingredient: asciminib hydrochloride.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XOLAIR omalizumab (rch) 75 mg solution for injection pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XOLAIR omalizumab (rch) 300 mg solution for injection pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XOLAIR omalizumab (rch) 150 mg solution for injection pre-filled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XOLAIR omalizumab (rch) 300 mg solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FABHALTA iptacopan 200 mg hard capsules blister pack.
-
Nov-2024Prescription medicine evaluationActive ingredient: onasemnogene abeparvovec.